You just read:

At Six Month Post-Launch, Nearly One Half of Surveyed U.S. Oncologists Have Prescribed Boehringer Ingelheim's Gilotrif for Non-Small-Cell Lung Cancer

News provided by

Decision Resources Group

Apr 24, 2014, 01:00 ET